MOH — authorised 25 October 2022
- Marketing authorisation holder: JANSSEN BIOTECH
- Status: likely_approved
MOH authorised Bcmaxcd3 on 25 October 2022
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. MOH authorised it on 25 October 2022.
JANSSEN BIOTECH holds the UAE marketing authorisation.